Key Highlights

● Johnson & Johnson touched a 52-week high on Friday, October 30, 2026.

● The company had no news of its own.

● Health care hit a record high as investors left AI and chip stocks.

● The Dow fell 572.25 points to 51,770.31.

Johnson & Johnson (NYSE:JNJ) touched a 52-week high on Friday, October 30, 2026, according to market data, standing out on a day when the Dow Jones Industrial Average fell 572.25 points to 51,770.31. The pharmaceutical and medical-technology giant had no company-specific news of its own. Its shares moved with the health care sector and the broader shift into defensive stocks.

That shift was the defining trade of the session. Investors pulled money out of AI, semiconductor and megacap technology stocks and moved it into energy, consumer staples, health care and utilities. Health care hit a record high, according to market data, while technology was by far the weakest of the 11 S&P 500 sectors.

What drove the rotation

The selling began with Intel (NASDAQ:INTC), whose weak fourth-quarter outlook and warning of cash burn sent its shares to a record one-day decline and dragged the Philadelphia Semiconductor index down to 10,688.80. Amazon (NASDAQ:AMZN)'s report, showing negative trailing free Cash Flow of $42.4 billion as AI spending ballooned, added to worries that the costs of the AI buildout are outrunning the cash it produces. Alphabet (NASDAQ:GOOGL) was still feeling the effects of its worst day ever on Thursday.

The S&P 500 fell 140.32 points to 7,580.07, and the Nasdaq Composite slid 747.73 points to 25,437.00, its worst day since June 5. Six of the 11 S&P 500 sectors still finished higher, and the equal-weight S&P 500 fell much less than the cap-weighted index, signaling that the pain was concentrated in the biggest technology names.

A broad health care rally

Johnson & Johnson had plenty of company. Pfizer (NYSE:PFE) and Cardinal Health also reached 52-week highs on the day, and Eli Lilly (NYSE:LLY) hit one as well on defensive buying, a day after its third-quarter report. AbbVie (NYSE:ABBV) climbed to a 52-week high after reporting third-quarter Revenue of $17.404 billion and raising its full-year adjusted Earnings forecast to $13.95 to $13.99 a share.

Regeneron (NASDAQ:REGN) was the S&P 500's top gainer after third-quarter revenue of $5.12 billion beat the $4.54 billion estimate. Gilead Sciences (NASDAQ:GILD) rose after non-GAAP earnings of $2.55 a share topped expectations of about $1.78, and DexCom gained after its results and a buyback authorization of up to $1 billion.

Not every health care stock joined in. Illumina (NASDAQ:ILMN) and Stryker (NYSE:SYK) fell after their quarterly reports disappointed investors.

A defensive stance amid rate worries

The rotation into health care came against a hawkish backdrop. The Federal Reserve held rates steady this week in a 10-2 vote, with two dissenters preferring a hike, and three Fed officials said on Friday that rates need to be higher. CME FedWatch data pointed to a likely December hike. Oil prices added to Inflation worries, with December WTI crude settling at $104.12 amid tensions around Iran.

"The love-hate relationship with tech and AI continues, and investors are becoming more discerning following earnings," a senior market strategist said on Thursday.

What to watch

Health care earnings continue next week. Pfizer reports on Tuesday, November 3, which is also the day of the midterm elections. Investors will also watch ISM purchasing managers data and the October jobs report on Friday, November 6.

For Johnson & Johnson, the key question is whether the money flowing into defensive sectors stays put if the technology selloff eases. October showed how strong that trend has been: health care, utilities and consumer staples were among the best-performing sectors of the month, while technology and communication services were the only two of 11 sectors to decline.